Acknowledging the scarcity of patients with concurrent POL-MUTs and PBRM1 mutations in publicly available immunotherapy cohorts, we explored the role of POL and PBRM1 co-mutation in two large pan-cancer cohorts: the MSKCC metastasis cancer cohort18 and the TCGA pan-cancer cohort.19 All patients in these cohorts were classified into four groups: both POL and PBRM1 wild type (WT), only POL-MUT (POL-o), only PRBM1 (PBRM1-o) and POL-PBRM1 co-mutation (POL&PBRM1) respectively. Here, PBRM1 is linked to cancer.